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Epidemiology of non-alcoholic fatty liver disease in Chinaq
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2Australian National University Medical School at The Canberra Hospital, Canberra, PO Box 11, Woden Act 2606, AustraliaFatty liver (steatosis) is highly prevalent in China and is more often linked to obesity than to alcoholism. Among more
aﬄuent regions of China, the community prevalence of non-alcoholic fatty liver disease (NAFLD) is 15%. With the
increasing pandemic of obesity, the prevalence of NAFLD has approximately doubled in the past decade. The risk factors
resemble those in other ethnic populations, but it is important to note that ethnic-speciﬁc deﬁnitions of central obesity,
obesity and metabolic syndrome are more useful in assessment of Chinese people. The full range of histological manifes-
tations of NAFLD has been demonstrated in Chinese patients, but to date hepatic severity is generally mild. In contrast to
chronic hepatitis C, steatosis is less common in patients with chronic hepatitis B; it is associated with metabolic, and not
viral factors and does not appear to aﬀect disease severity. Although long-term outcomes of NAFLD in Chinese popula-
tions remain unclear, it may be a predictor of metabolic disorders, diabetes and cardiovascular disease. Public health inter-
ventions are therefore indicated to halt or reverse the national trend of obesity in China so as to improve liver as well as
metabolic health.
 2008 European Association for the study of the Liver. Published by Elsevier B.V. All rights reserved.
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Non-alcoholic fatty liver disease (NAFLD) is an
acquired metabolic stress-related liver disorder that
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NAFLD now aﬀects 20–30% of the general population
in North America and similar countries [1,2]. However,
obesity and insulin resistance, the common substrates
of NAFLD, are not restricted to the West, as witnessed
by their increasingly universal distribution [1,3–6].
Recently, the once ‘‘lean” Chinese are facing a weight
problem that is growing rapidly [4,5]. According to the
ﬁrst comprehensive National Health Survey on the
China mainland conducted in 2004, 60 million (4.6%
of the population) are obese, 200 million (15%) over-
weight, 20 million (1.5%) have type 2 diabetes mellitus
(T2DM), and 160 million (12%) have high blood pres-
sure [4,5]. The steadily increasing prevalence of obesity,
coupled with T2DM, dyslipidemia, hypertension and
ultimately the metabolic syndrome (MetS) has put a
very large proportion of the Chinese population at risk
of developing NAFLD in the coming decades [3,6].
NAFLD is therefore emerging into a new signiﬁcant
health problem in a country [3,6], where, traditionally,
clinicians have dealt with the formidable burden of
chronic hepatitis B virus (HBV) infection [2,7].ublished by Elsevier B.V. All rights reserved.
Table 1
Revised criteria of metabolic syndrome used in Chinese studies
The metabolic syndrome is deﬁned by any three of the following
factors
Central obesity Waist circumference P90 cm
(male), P80 cm (female)
and/or and or
Obesity BMIP 25 kg/m2 in both sexes
Hypertriglyceridaemia Triglycerides P1.7 mmol/L
Reduced HDL-C LDL-C <1.03 mmol/L (male) and
<1.29 mmol/L (female)
Raised blood pressure Blood pressure P130/85 mmHg
Raised fasting plasma glucose FPG P6.1 mmol/L, or previous
diagnosed type 2 diabetes
BMI, body mass index; HDL-C, high-density-lipoprotein cholesterol;
LDL-C, low-density-lipoprotein cholesterol; FPG, fasting plasma
glucose.
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China
NAFLD encompasses a spectrum of liver disorders
characterized by macrovesicular hepatic fat accumula-
tion alone (simple steatosis), or accompanied by signs
of hepatocyte injury, mixed inﬂammatory cell inﬁltrate,
and variable hepatic ﬁbrosis in pericellular distribution
(non-alcoholic steatohepatitis, NASH); NASH may lead
to cirrhosis and hepatocellular carcinoma (HCC) [1,8].
Although histological examination remains the gold
standard for the diagnosis of NASH, pathological deﬁ-
nition is often not possible in community-based research
studies and clinical practice settings [1,3]. Alternatively,
operational deﬁnitions of NAFLD have been proposed
in which biochemical criteria and hepatic imaging (ultra-
sonography, computed tomography, and magnetic reso-
nance imaging) are used [9–12]. Among them,
ultrasonographic deﬁnition of steatosis has most fre-
quently been used in Chinese epidemiological research
studies [3,6,9–11], and this approach has been endorsed
by Asia-Paciﬁc regional guidelines [12].
Diagnosis of fatty liver by ultrasonography is deﬁned
by the presence of at least two of three abnormal ﬁnd-
ings: diﬀusely increased echogenicity (‘bright’) liver –
with liver echogenicity greater than kidney or spleen,
vascular blurring, and deep attenuation of ultrasound
signal [9]. In addition, other liver diseases should be
excluded [8–12]. In recent studies, the etiology of steato-
sis has been further deﬁned according to the Chinese
Liver Disease Association criteria of 2003 [10], which
include alcoholic fatty liver disease (alcohol consump-
tion more than 40 g per day for more than 5 years),
NAFLD (non-drinkers, or alcohol consumption less
than 40 g per week for the past 12 months, and life-time
cumulative consumption less than 100 kg), and steatosis
related to other etiologies, such as chronic hepatitis C
(CHC) [10,11]. The working deﬁnition of NAFLD in
China is generally consistent with the recently published
2007 Guidelines for the Assessment and Management of
NAFLD in the Asia-Paciﬁc region [10–12]. However,
given the high prevalence of both MetS (15%) and
chronic HBV infection (10%) in the general Chinese
population [2,5,7], it is likely that NAFLD could co-
exist with other liver diseases [13–15].
Body mass index (BMI) and waist circumference are
the best predictors of NAFLD, as well as of metabolic
disorders such as T2DM, dyslipidemia, and MetS [6].
However, only 2–3% of Asians would be classiﬁed as
obese by Western criteria [6,16]. It is well known that
there is a higher proportion of visceral fat and a lower
proportion lean body mass in Asians than in Caucasians
with the same BMI [17]. Therefore, regional deﬁnitions
of central obesity, obesity and MetS have been used
widely in Chinese studies [4–6,16]; these are summarized
in Table 1.3. Prevalence of NAFLD in China
Globally, the incidence of NAFLD remains unknown
because no prospective studies have been conducted
[1–3,6]. Further, the point prevalence of NAFLD at
each of its diﬀerent stages (simple steatosis, NASH, cir-
rhosis) remains poorly deﬁned throughout the world
[1–3,6]. The reported point prevalence of NAFLD varies
widely, mainly based on the information available in a
given population and the diagnostic criteria used [1–3].
From mainland China, ultrasound surveys for fatty liver
(any cause) were ﬁrst published in the mid-1990s [14].
The median prevalence of ultrasonographic steatosis in
Chinese populations was 10%, but ranged from 1%
to more than 30% [14,15]. The factors identiﬁed to cor-
relate with such variability included age, gender and
geographic locality (urban higher than rural, eastern
coast higher than inland), as well as the precise criteria
used for disease deﬁnition [14,15]. In addition, the prev-
alence of fatty liver varied by occupation, being highest
in administrative oﬃcers and white collars, followed (in
order) by laborers, peasants, and monks [14]. The rea-
sons for the latter diﬀerences in terms of diet, physical
activity or other factors have not yet been explored.
Recent studies indicate that prevalence of fatty liver
in the general population of Shanghai (East China)
and Guangdong (South China) are 17% and 15%,
respectively [18,19]. In these surveys, ultrasonographi-
cally detected steatosis was more strongly associated
with obesity than with heavy drinking [18,19], although
the latter remains important in some other regions of
China [20]. Further, nearly 90% of cases of fatty liver
appeared attributable to metabolic factors (NAFLD),
the prevalence of which was therefore established to be
between 12% and 15% of the general adult population
[18,19]. The point prevalence of NAFLD in children
and adolescents between the age of 7 and 18 years was
reported to be 1.3% in Guangdong [19]. Similar ﬁndings
have been observed in epidemiological surveys from
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have published in Chinese but not English) [14,15]. In
addition, the prevalence of NAFLD in Hong Kong Chi-
nese was 16% [21], and in an adult population of Taiwan
it was 12% [22].
Of particular interest, the prevalence of fatty liver in
Shanghai and Wuhan (capital of Hubei province, central
China) has approximately doubled in the past 7–10
years [23,24]. Speciﬁcally, it has increased from 13% to
25% in participants of routine health examinations in
the Shuiguohu district of Wuhan [24], and from 4% to
14% in Shanghai BaoSteel Group employees [23].
Among the latter, the prevalence of fatty liver in partic-
ipants with elevated serum alanine aminotransferase
(ALT) levels (>40 U/L) increased from 26% to 51%
between 1995 and 2002 [23]. There is strong evidence
that the substantially increased prevalence of fatty liver
in the studied population during the last decade is in
parallel with regional trends in over-nutrition, obesity,
T2DM, dyslipidemia, and MetS [4,5,23]. Conversely,
the prevalence of habitual alcohol drinking did not
change over the study period [23]. NAFLD is now
becoming a major cause of asymptomatic elevation of
liver enzymes among those participating in regular
health examinations on the China mainland and in
Taiwan [23,25]. Finally, the present upward trends in
the obesity and T2DM pandemic lead us to forecast a
further increase in NAFLD prevalence in the immediate
future [4–6].4. Risk factors for NAFLD in Chinese patients
A detailed analysis of the available epidemiological
data shows that risk factors for NAFLD in China
resemble those in the West and in other regions of Asia
[6]. The major ones are central obesity, obesity, dyslipi-
demia, T2DM, arterial hypertension, insulin resistance,
for example, as measured by the homoeostasis model
assessment-insulin resistance (HOMA-IR), and MetS
[6,14–16,18–22,25–30]. On one hand, MetS is a strong
predictor of NAFLD [6,16,29,30]. On the other hand,
NAFLD is a good predictor for the clustering of compo-
nents of risk factors for MetS [30]. In a recent Hong
Kong study, hypoadiponectinemia was associated with
NAFLD (vs. controls), while serum tumor necrosis fac-
tor-alpha (TNF-a) levels (as well as BMI) were indepen-
dent factors for NASH (vs. simple steatosis) [31]. Other
work has shown that low serum adiponectin levels cor-
relate with steatosis severity, and with necroinﬂammato-
ry severity of NAFLD (i.e., the presence of NASH
versus simple steatosis) [8,32]. In addition, impaired glu-
cose tolerance (IGT) without elevation of fasting plasma
glucose (FPG) is common among Hong Kong Chinese
patients with NAFLD and no history of T2DM [33].
In a large international study, IGT was associated withhistologically severe liver disease in NAFLD [34], but
the study by Wong and colleagues indicated that histo-
logical severity could not be accurately predicted by
any FPG cut-oﬀ [33].
It is often stated that there are apparent diﬀerences in
risk factors for NAFLD between Chinese and Cauca-
sians, particularly a perception that NAFLD can occur
in ‘‘lean” Asians, but not Europeans [6,16]. This could
be because inappropriate anthropometric criteria have
been used for waist circumference and BMI in Asians
[4–6,16]. Even the use of the ethnic-speciﬁc overweight
and obesity criteria reveals a relatively high proportion
(40%) of Chinese NAFLD patients with normal BMI
[22,27]. However, it should be emphasized that the dis-
tribution of adiposity (fat storage tissue) may be more
important to hepatic steatosis than the total adipose
mass [6,35]. In particular, visceral adipose mass is the
most important factor for the development of hepatic
steatosis in both Asians and Europeans, independent
of the total adipose mass and BMI [6,35–37].
In addition to metabolic disorders, a number of other
risk factors for NAFLD have been identiﬁed from Chi-
nese studies [6,14–16,18,19,26]. These include advancing
age, male gender (see below), lower education, physical
inactivity, daytime somnolence, high fat intake, overeat-
ing, recent weight gain, expanding waist circumference,
and family history of MetS components and cardiovas-
cular disease [6,14–16,18,19,26]. On the other hand,
there is no association between current cigarette smok-
ing or history of chronic viral hepatitis and NAFLD
in Chinese patients [18,38]. Recently, a study from
Guangdong Province showed that single nucleotide
polymorphisms (SNPs) in the gene for peroxisome pro-
liferator-activated receptor-gamma (PPAR-c), but not
its co-activator-1a (PGC-1a), is associated with individ-
ual susceptibility to NAFLD, possibly through the
adiponectin pathway [39]. However, another similar
study from Hong Kong failed to identify any association
between adiponectin and TNF-a gene polymorphisms
and biopsy-proven NAFLD, or with signiﬁcant hepatic
ﬁbrosis in this disorder [40].
As with many other features of MetS, advancing age
is associated with increasing prevalence of NAFLD in
Chinese population [6,14,18,19]. But female gender is
not a risk for NAFLD, in fact men outnumber women
in most of the published series [6,14,15]. A biomodal
age distribution has been observed in several studies
[18,19,27]. As for cardiovascular disease, the peak prev-
alence of NAFLD occurs earlier (40–49 years) in men
than in women (over 50 years), see Fig. 1 [6,18].
Contrary to the numerous risk factors, there are a few
protective factors against NAFLD in China that have
been described. These include more exercise, working
under moderate stress, and, seemingly paradoxically,
mild alcohol consumption [26]. In these studies, mild
alcohol consumption was deﬁned as average alcohol
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Fig. 1. Prevalence of fatty liver among 3175 Shanghai adults. Adapted
from Fan et al. [6,18], with permission.
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studies, mild to moderate alcohol consumption was
found to be associated with a lower prevalence of hyper-
insulinemia and MetS [41–43]. Thus, light alcohol drink-
ing could reduce the incidence of NAFLD by improving
insulin resistance. The reason for the apparent protec-
tive of moderate stress against NAFLD has not yet been
explored, but sympathetic nervous system activity and
increased basal metabolic rate would be theoretical
possibilities.5. Clinical settings of Chinese patients with NAFLD
Although NAFLD appears to be the commonest
cause of elevated ALT and liver injury in healthy Chi-
nese adults [23,25], it currently comprises a low propor-
tion of cases of chronic liver disease in both inpatient
and outpatient series from tertiary referral hospitals
[44,45]. Thus, the records of the liver clinic of Queen
Mary Hospital (Hong Kong) show that chronic hepati-
tis B (CHB) remains the most common reason for refer-
ral with chronic liver disease (89% of cases), followed by
CHC (5%), alcoholic liver disease (1.7%) and NAFLD
(1.5%) [44]. Among cases of chronic hepatitis of
unknown etiology, the prevalence of biopsy-proven
NASH was found to be 16% (15/97) [45], and in patients
with morbid obesity it was 34% (54/160) [13].
In accord with international experience, most
patients with NAFLD have no symptoms speciﬁc to
liver disease, the full range of histological manifestations
of NAFLD has been demonstrated in Chinese patients,
from simple steatosis, through NASH to cirrhosis
[28,46–48]. As in North America, Australia and Europe,
T2DM is the most important predictor of severe histo-
logical disease, and of more frequently abnormal liver
function tests among patients with NAFLD
[6,27,34,47,49]. However, the histological severity of ste-
atohepatitis and ﬁbrosis are generally mild in most
Chinese patients with biopsy-proven NAFLD, and
bridging ﬁbrosis or cirrhosis have seldom been foundin Chinese liver biopsy samples [13,28,45–50]. This phe-
nomenon might be partly due to the relatively short
duration and possibly mild degree of the underlying
obesity and related metabolic disorders in Chinese
patients with NAFLD at initial liver biopsy. NAFLD-
related decompensated cirrhosis and HCC does not yet
appear to have been reported from the China mainland
or Hong Kong, and only one case of esophageal variceal
bleeding arising from NAFLD-related cirrhosis has
been reported from Taiwan [51].
The natural history of NAFLD globally is currently
diﬃcult to assess, but there is mounting evidence that
some patients may eventually develop cirrhosis and
HCC [8]. In the only available paired biopsy study of
NAFLD in Hong Kong [47], 9 patients (53%) had pro-
gressive disease with worsening of ﬁbrosis score, but no
patient developed hepatic decompensation or HCC after
a median follow up of 6 years. This is a short follow-up
for this slowly progressive, relapsing and resulting disor-
der. What may be more salient is the risk of metabolic
disorders in Chinese people with steatosis; seven patients
(41%) of the Hong Kong study cohort developed hyper-
tension or T2DM during follow-up[47], revealing the
importance of diagnosing NAFLD for prevention and
early detection of these metabolic and cardiovascular
disorders.
As an indolent form of chronic liver disease, NAFLD
may be even less important than primary biliary cirrho-
sis in Chinese [52], but it need to be appreciated that
patients with NAFLD are not expected to develop com-
plications of cirrhosis until late in life [8]. To date, pro-
spective studies in Chinese are too short in duration to
exclude late liver complications of NAFLD. Being a
recent phenomenon in Chinese hepatology, large, long-
term prospective cohort studies, ideally with paired liver
biopsy samples, are required to deﬁne the natural his-
tory and impact of NAFLD for causing serious signiﬁ-
cant chronic liver disease. The contribution this could
make to the HCC burden in Chinese patients also
require further study, as both obesity and T2DM
increase risk of HCC for CHB and CHC [6,53]. On
the other hand, although serum ALT levels often
decrease over time in patients with NAFLD followed
for up to 6 years, a signiﬁcant proportion develop dysl-
ipidemia, IGT/T2DM or hypertension soon after the
diagnosis of NAFLD, even in once non-obese individu-
als [54]. Thus, the importance of NAFLD may not only
be as a liver disease, but more particularly as a predic-
tor, or even an early mediator of T2DM and MetS
[55,56].6. NAFLD and chronic viral hepatitis in China
Over half a billion of the world’s population is
chronically infected with HBV and hepatitis C virus
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thirds of the world’s cases with chronic HBV infection
[2,7]. However, only a proportion of these individuals
will develop CHB or CHC, which are progressive liver
diseases [2,7]. It is therefore critical to identify which fac-
tors contribute to accelerated liver injury and a poor
outcome [57,58]. In patients with CHC, hepatic steatosis
is one such variable associated with cirrhosis and HCC
[57]. It is well known that hepatic steatosis is a histolog-
ical feature in approximately 50% of patients with CHC.
HCV genotypes 2 and 3 directly induce hepatic steatosis,
whereas insulin resistance plays a key role in genotypes 1
and 4 HCV infection [57]. The prevalence of non-alco-
holic steatosis by ultrasonography in HCV genotype 3
infection was signiﬁcantly higher than that of other
genotypes (39% vs. 11%) in 98 Chinese patients with
CHC [59]. Moreover, steatosis and host obesity were
associated with reduced sustained viral response (SVR)
to antiviral therapy according to univariate analysis
[59]. The level of plasma insulin and HOMA-IR
appeared to be independent factors for predicting SVR
in this small cohort [59]. Since the prevalence of HCV
infection in the Chinese urban population is low and
has been stable over the past 10 years [60,61], chronic
HCV infection could not be attribute to the increased
prevalence of steatosis in China.
In contrast to CHC, steatosis in persons with CHB is
a reﬂection of the host metabolic proﬁle; it does not cor-
relate with viral factor (such as hepatitis B e antigen sta-
tus or HBV DNA titer). The prevalence of histological
steatosis is relatively low, being 37% among a total of
849 patients with CHB from seven studies outside of
China [58]. However, persons with signiﬁcant alcohol
intake were not excluded in some of these studies.
According to one study from Taiwan, the prevalence
of CHB in morbid obesity patients was 16% (26/160),
of which three cases had bridging ﬁbrosis and/or cirrho-
sis, but no cirrhosis was found in the NASH group with-
out HBV infection [13]. A recent study of 1915 patients
with chronic CHB infection from Hangzhou (capital of
Zhejiang Province, east China) excluded patients co-
infected with HCV, HIV, and alcoholic liver disease. It
showed that steatosis by ultrasonography was present
in 153 (8%) cases [62], while histological evidence of ste-
atosis was observed in 260 (14%) of liver biopsies
[62,63]. Moreover, histological steatosis was associated
with metabolic factors not viral ones in Chinese patients
with CHB, and it does not appear to inﬂuence the sever-
ity of hepatic necroinﬂammatory activity or liver ﬁbrosis
stage [63]. Given this strong association with metabolic
risk factors, steatosis in patients with CHB should be
regarded as NAFLD; and the concurrence of NAFLD
in people with chronic HBV infection appears to be no
higher than that observed in the general population
[1–3,14,18]. According to one early study from Shang-
hai, the prevalence of NAFLD in participants who wereseropositive for hepatitis B surface antigen (HBsAg) was
even less than HBsAg-negative counterparts (8% vs.
15%) [26,64]. This could partly be due to an inverse rela-
tionship between the presence of MetS and serum
HBsAg-positive status in Chinese people [65,66]. There-
fore, persons with chronic HBV infection are not a high-
risk population for NAFLD. In persons with inactive or
low-level chronic HBV infection who also have steatosis
and coexisting MetS components, it may be prudent to
seek strategies that can reduce liver fat content so as
to prevent potentially hazardous metabolic or cardio-
vascular complications [12,55,56,58].7. Conclusions
NAFLD is no longer a disease exclusive to devel-
oped Western countries. It should be regarded as a
global problem. In China, steatosis (15% urban pop-
ulation) is mainly related to obesity and MetS, not
alcohol. Although steatosis is common in patients with
CHC, the prevalence of HCV infection in Chinese
urban population is low and has remained stable over
the past decade. Unlike CHC, steatosis is less common
(14%) in CHB; it is not related directly to the viral
infection so much as to the same metabolic factors
that cause NAFLD. Therefore, neither alcohol nor
chronic viral infection (HBV, HCV) accounts for the
rapidly increased prevalence of steatosis in China.
With the increasing pandemic of overweight and obes-
ity in the Chinese population, China is likely to har-
bor an increasing reservoir of patients with NAFLD.
The risk factors and clinical settings resemble to those
of Caucasian counterparts, although there are substan-
tial diﬀerences in the extent of visceral adiposity
between Asians and Europeans. NAFLD appears to
be associated with insulin resistance and represents
the hepatic manifestation of MetS. Not surprisingly,
therefore, patients with NAFLD are at high risk of
developing of metabolic complications, perhaps much
higher than their risk of liver cirrhosis. In contempo-
rary clinical practice, it has become mandatory to
evaluate metabolic risk factors in NAFLD patients,
and to consider careful surveillance and appropriate
lifestyle modiﬁcation and anti-obesity therapy not only
of resultant liver disease, but also of the underlying
metabolic complications. Ultimately, though public
health initiatives and long-term preventive strategies
hold the key to halt or reverse the pandemic of obesity
and the possible onset of liver-related complications of
NAFLD in China.References
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